The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex

G protein-coupled receptors (GPCRs) mediate the majority of physiologic responses to hormones and neurotransmitters. However, many GPCRs exhibit varying degrees of agonist-independent G protein activation. This phenomenon is referred to as basal or constitutive activity. For many of these GPCRs, drugs classified as inverse agonists can suppress basal activity. There is a growing body of evidence that basal activity is physiologically relevant, and the ability of a drug to inhibit basal activity may influence its therapeutic properties. However, the molecular mechanism for basal activation and inhibition of basal activity by inverse agonists is poorly understood and difficult to study, because the basally active state is short-lived and represents a minor fraction of receptor conformations. Here, we investigate basal activation of the G protein Gs by the β2 adrenergic receptor (β2AR) by using purified receptor reconstituted into recombinant HDL particles with a stoichiometric excess of Gs. The β2AR is site-specifically labeled with a small, environmentally sensitive fluorophore enabling direct monitoring of agonist- and Gs-induced conformational changes. In the absence of an agonist, the β2AR and Gs can be trapped in a complex by enzymatic depletion of guanine nucleotides. Formation of the complex is enhanced by the agonist isoproterenol, and it rapidly dissociates on exposure to concentrations of GTP and GDP found in the cytoplasm. The inverse agonist ICI prevents formation of the β2AR-Gs complex, but has little effect on preformed complexes. These results provide insights into G protein-induced conformational changes in the β2AR and the structural basis for ligand efficacy.

[1]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[2]  Michel Bouvier,et al.  Real-time monitoring of receptor and G-protein interactions in living cells , 2005, Nature Methods.

[3]  B. Kobilka,et al.  Different Effects of Gsα Splice Variants on β2-Adrenoreceptor-mediated Signaling , 1998, The Journal of Biological Chemistry.

[4]  T. Kenakin,et al.  Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor , 1995, Nature.

[5]  A. Tinker,et al.  Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Pascale G. Charest,et al.  β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Yoshinori Shichida,et al.  Functional role of internal water molecules in rhodopsin revealed by x-ray crystallography , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Jie Liang,et al.  CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues , 2006, Nucleic Acids Res..

[9]  Manfred Burghammer,et al.  Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.

[10]  B. Kobilka,et al.  Different effects of Gsalpha splice variants on beta2-adrenoreceptor-mediated signaling. The Beta2-adrenoreceptor coupled to the long splice variant of Gsalpha has properties of a constitutively active receptor. , 1998, The Journal of biological chemistry.

[11]  Patrick Scheerer,et al.  Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.

[12]  Marcus Elstner,et al.  The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. , 2004, Journal of molecular biology.

[13]  Tsutomu Kouyama,et al.  Crystal structure of squid rhodopsin , 2008, Nature.

[14]  M. Bouvier,et al.  Allosteric effects of G protein overexpression on the binding of beta-adrenergic ligands with distinct inverse efficacies. , 2001, Molecular pharmacology.

[15]  K. Palczewski,et al.  X-Ray diffraction analysis of three-dimensional crystals of bovine rhodopsin obtained from mixed micelles. , 2000, Journal of structural biology.

[16]  P. Chidiac,et al.  Inverse agonist activity of beta-adrenergic antagonists. , 1994, Molecular pharmacology.

[17]  Xavier Deupi,et al.  Coupling ligand structure to specific conformational switches in the β2-adrenoceptor , 2006, Nature chemical biology.

[18]  R. Lefkowitz,et al.  The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. , 2002, Journal of cell science.

[19]  J. Ballesteros,et al.  Activation of the β2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6* , 2001, The Journal of Biological Chemistry.

[20]  M. Lohse,et al.  Molecular basis of inverse agonism in a G protein–coupled receptor , 2005, Nature chemical biology.

[21]  P. Heyworth,et al.  Absolute requirement for GTP in activation of human neutrophil NADPH oxidase in a cell-free system: role of ATP in regenerating GTP. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Lohse,et al.  Dynamics of receptor/G protein coupling in living cells , 2005, The EMBO journal.

[23]  Douglas M. Yau,et al.  A new approach to producing functional G alpha subunits yields the activated and deactivated structures of G alpha(12/13) proteins. , 2006, Biochemistry.

[24]  Richard N. Zare,et al.  A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein , 2007, Proceedings of the National Academy of Sciences.

[25]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[26]  Yang Xiang,et al.  Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. , 2004, The Journal of biological chemistry.

[27]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[28]  P Ghanouni,et al.  Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H Weinstein,et al.  Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor , 1997, The EMBO journal.

[30]  D C Teller,et al.  Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). , 2001, Biochemistry.

[31]  R. Lefkowitz,et al.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.

[32]  P Ghanouni,et al.  Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor* , 2001, The Journal of Biological Chemistry.

[33]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[34]  A. T. Bentley,et al.  Origin of guanine nucleotides in isolated heart mitochondria. , 1999, Biochemical and biophysical research communications.

[35]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[36]  Tetsuya Hori,et al.  Crystal Structure of Squid Rhodopsin with Intracellularly Extended Cytoplasmic Region , 2008, Journal of Biological Chemistry.

[37]  F Guarnieri,et al.  Agonist-induced Conformational Changes at the Cytoplasmic Side of Transmembrane Segment 6 in the β2 Adrenergic Receptor Mapped by Site-selective Fluorescent Labeling* , 2001, The Journal of Biological Chemistry.

[38]  Robert J. Lefkowitz,et al.  A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling , 2007, Proceedings of the National Academy of Sciences.

[39]  R. Lefkowitz,et al.  Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. , 1994, Molecular pharmacology.

[40]  S. Sprang,et al.  Crystal structure of the adenylyl cyclase activator Gsalpha. , 1997, Science.

[41]  A. Gilman,et al.  Purification of Recombinant G Proteins from Sf9 Cells by Hexahistidine Tagging of Associated Subunits , 1995, The Journal of Biological Chemistry.

[42]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[43]  M. Maguire,et al.  Relationship between the beta-adrenergic receptor and adenylate cyclase. , 1977, The Journal of biological chemistry.

[44]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[45]  C. Altenbach,et al.  High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation , 2008, Proceedings of the National Academy of Sciences.

[46]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[47]  Pascale G. Charest,et al.  Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Xavier Deupi,et al.  Probing the β2 Adrenoceptor Binding Site with Catechol Reveals Differences in Binding and Activation by Agonists and Partial Agonists* , 2005, Journal of Biological Chemistry.

[49]  H. Hamm,et al.  GTPase mechanism of Gproteins from the 1.7-Å crystal structure of transducin α - GDP AIF−4 , 1994, Nature.

[50]  R. Zare,et al.  Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies. , 2007, The Journal of biological chemistry.

[51]  T. Kenakin Pharmacological Onomastics: What's in a name? , 2008, British journal of pharmacology.